1. Novel Pyridine Bioisostere of Cabozantinib as a Potent c -Met Kinase Inhibitor: Synthesis and Anti-Tumor Activity against Hepatocellular Carcinoma.
- Author
-
Karmacharya U, Guragain D, Chaudhary P, Jee JG, Kim JA, and Jeong BS
- Subjects
- Anilides chemical synthesis, Animals, Antineoplastic Agents pharmacology, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular metabolism, Carcinoma, Hepatocellular pathology, Cell Line, Tumor, Disease Models, Animal, Dose-Response Relationship, Drug, Humans, Liver Neoplasms drug therapy, Liver Neoplasms metabolism, Liver Neoplasms pathology, Mice, Molecular Structure, Protein Kinase Inhibitors chemical synthesis, Pyridines chemical synthesis, Xenograft Model Antitumor Assays, Anilides pharmacology, Protein Kinase Inhibitors pharmacology, Proto-Oncogene Proteins c-met antagonists & inhibitors, Pyridines pharmacology
- Abstract
Two novel bioisosteres of cabozantinib, 3 and 4 , were designed and synthesized. The benzene ring in the center of the cabozantinib structure was replaced by trimethylpyridine ( 3 ) and pyridine ( 4 ), respectively. Surprisingly, the two compounds showed extremely contrasting mesenchymal-epithelial transition factor ( c -Met) inhibitory activities at 1 μM concentration (4% inhibition of 3 vs. 94% inhibition of 4 ). The IC
50 value of compound 4 was 4.9 nM, similar to that of cabozantinib (5.4 nM). A ligand-based docking study suggested that 4 includes the preferred conformation for the binding to c -Met in the conformational ensemble, but 3 does not. The anti-proliferative activity of compound 4 against hepatocellular carcinoma (Hep3B and Huh7) and non-small-cell lung cancer (A549 and H1299) cell lines was better than that of cabozantinib, whereas 3 did not show a significant anti-proliferative activity. Moreover, the tumor selectivity of compound 4 toward hepatocellular carcinoma cell lines was higher than that of cabozantinib. In the xenograft chick tumor model, compound 4 inhibited Hep3B tumor growth to a much greater extent than cabozantinib. The present study suggests that compound 4 may be a good therapeutic candidate against hepatocellular carcinoma.- Published
- 2021
- Full Text
- View/download PDF